论文部分内容阅读
目的探讨晚期胃癌患者一线化疗前后血红蛋白水平变化与预后及化疗疗效的关系。方法收集84例晚期胃癌患者的临床资料,应用SPSS 20.0软件对一线化疗前后血红蛋白变化与晚期胃癌患者的化疗疗效及生存的关系进行分析。结果疾病进展患者化疗前后血红蛋白均值分别为(120.17±22.54)和(97.17±21.67)g/L(P=0.017),有内脏转移的患者化疗前后血红蛋白均值分别为(115.66±19.05)和(109.11±17.73)g/L(P=0.012),有肝脏转移的患者化疗前后血红蛋白均值分别为(116.40±17.57)和(110.13±17.64)g/L(P=0.015)。未见血红蛋白变化与患者年龄、ECOG评分、病理分型、病灶位置和有无腹膜转移等因素相关。生存分析显示化疗前贫血的胃癌患者预后较差,但差异无统计学意义(P=0.119)。结论晚期胃癌患者血红蛋白降低与化疗疗效有关,化疗后血红蛋白降低提示较差的疗效。化疗前无贫血的胃癌患者显示出较好的预后。
Objective To investigate the relationship between the changes of hemoglobin level and prognosis and the curative effect of chemotherapy in patients with advanced gastric cancer before and after first-line chemotherapy. Methods The clinical data of 84 patients with advanced gastric cancer were collected. The relationship between hemoglobin before and after first-line chemotherapy and chemotherapy efficacy and survival in patients with advanced gastric cancer were analyzed by SPSS 20.0 software. Results The mean hemoglobin before and after chemotherapy was (120.17 ± 22.54) and (97.17 ± 21.67) g / L, respectively (P = 0.017). The mean hemoglobin before and after chemotherapy in patients with visceral metastasis was (115.66 ± 19.05) and (109.11 ± 17.73) g / L (P = 0.012). The mean hemoglobin before and after chemotherapy in patients with liver metastasis was (116.40 ± 17.57) and (110.13 ± 17.64) g / L, respectively. No changes in hemoglobin and patient age, ECOG score, pathological type, location of the lesion and whether the peritoneal metastasis and other factors. Survival analysis showed that the prognosis of gastric cancer patients with pre-chemotherapy anemia was poor, but the difference was not statistically significant (P = 0.119). Conclusions The decrease of hemoglobin in patients with advanced gastric cancer is related to the curative effect of chemotherapy. The decrease of hemoglobin after chemotherapy suggests poor curative effect. Patients without anemia before chemotherapy showed a better prognosis.